NRXP – nrx pharmaceuticals, inc. (US:NASDAQ)

News

NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion [Yahoo! Finance]
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com